Wikiwand AI

Cadefrecitinib

Investigational TYK2 inhibitor drug From Wikipedia, the free encyclopedia

Cadefrecitinib is an investigational new drug that is being developed by Lakefront Biotherapeutics for the treatment of dermatomyositis and systemic lupus erythematosus. It is a TYK2 kinase inhibitor.[1][2][3]

Other namesGLPG3667
CAS Number
Quick facts Clinical data, Other names ...
Cadefrecitinib
Clinical data
Other namesGLPG3667
Identifiers
  • 4-methyl-5-[3-methyl-7-[(6-morpholin-4-ylpyridazin-3-yl)amino]imidazo[4,5-b]pyridin-5-yl]oxypyridine-2-carbonitrile
CAS Number
PubChem CID
IUPHAR/BPS
UNII
ChEMBL
Chemical and physical data
FormulaC22H21N9O2
Molar mass443.471 g·mol−1
3D model (JSmol)
  • CC1=CC(=NC=C1OC2=NC3=C(C(=C2)NC4=NN=C(C=C4)N5CCOCC5)N=CN3C)C#N
  • InChI=InChI=1S/C22H21N9O2/c1-14-9-15(11-23)24-12-17(14)33-20-10-16(21-22(27-20)30(2)13-25-21)26-18-3-4-19(29-28-18)31-5-7-32-8-6-31/h3-4,9-10,12-13H,5-8H2,1-2H3,(H,26,27,28)
  • Key:GXELZXDURVDKHP-UHFFFAOYSA-N
Close

References

Related Articles

Timelines

Top Qs

Fact Checks